Loading...
ROCO
4171
Market cap24mUSD
Jul 09, Last price  
17.10TWD
1D
0.29%
1Q
-8.06%
Jan 2017
21.02%
IPO
-40.95%
Name

GeneReach Biotechnology Corp

Chart & Performance

D1W1MN
ROCO:4171 chart
P/E
P/S
3.38
EPS
Div Yield, %
Shrs. gr., 5y
-0.14%
Rev. gr., 5y
-22.95%
Revenues
233m
+12.71%
365,795,000857,034,0001,012,077,000750,017,000225,460,000206,488,000232,741,000
Net income
-110m
L-7.12%
77,180,000257,284,000376,622,000221,337,000-166,270,000-118,734,000-110,281,000
CFO
-14m
L-40.30%
0169,819,000348,989,000357,633,000-38,673,000-23,224,000-13,864,000
Dividend
Jul 28, 20231.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.
IPO date
Nov 19, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT